Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
暂无分享,去创建一个
E A Emini | D. Richman | D. Havlir | J. Mellors | E. Emini | J. Chodakewitz | J. Eron | A. Meibohm | J. Eron | F. Valentine | R. Gulick | D D Richman | J J Eron | J A Chodakewitz | D McMahon | J W Mellors | L. Jonas | C. González | D. McMahon | F T Valentine | D Havlir | L Jonas | A Meibohm | R M Gulick | C Gonzalez | C. J. González
[1] S W Lagakos,et al. Analyzing laboratory marker changes in AIDS clinical trials. , 1991, Journal of acquired immune deficiency syndromes.
[2] I B Duncan,et al. Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.
[3] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[4] P. Darke,et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .
[6] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Dawson. Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures , 1994 .
[8] J. Goedert,et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.
[9] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[10] J. Sninsky,et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.
[11] R F Schinazi,et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.
[12] T. Merigan,et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.
[13] Victoria Johnson,et al. Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection , 1996, Annals of Internal Medicine.
[14] S D Kemp,et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Wainberg,et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine , 1993, Antimicrobial Agents and Chemotherapy.
[16] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[17] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[18] M. Murcko,et al. Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .
[19] A. McLean,et al. Lifespan of human lymphocyte subsets defined by CD45 isoforms , 1992, Nature.
[20] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[21] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[22] D. Kuritzkes,et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients , 1996, AIDS.
[23] S. Hammer,et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.
[24] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[25] P. Smith,et al. Lymphocyte Survival in Men treated with X-rays for Ankylosing Spondylitis , 1967, Nature.
[26] D. Kuritzkes,et al. Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .
[27] D. Ho,et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.
[28] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[29] L. M. Lehman,et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.